Risk of Cancer in 3 cm Barrett's Esophagus
A 3 cm segment of non-dysplastic Barrett's esophagus carries an annual cancer risk of approximately 0.3% per year, which translates to needing to surveil approximately 450 patients annually to detect one cancer. 1
Quantifying the Cancer Risk
The most recent 2025 AGA guideline provides the clearest risk stratification data. For Barrett's segments ≥3 cm, the annual progression rate to esophageal adenocarcinoma (EAC) is 0.31%, compared to only 0.06% for segments <3 cm 1. This represents a 5-fold higher risk when the segment reaches or exceeds 3 cm in length.
Breaking this down further:
- Per centimeter increase: Each additional centimeter of Barrett's length increases the odds of progression to high-grade dysplasia (HGD) or EAC by 25% (OR 1.25) 1
- Per 4 cm increase: The risk of progression to HGD or EAC doubles 1
- Number needed to surveil: To detect one cancer, 450 patients with long-segment Barrett's (≥3 cm) would need annual surveillance endoscopy 2
Clinical Context and Surveillance Implications
The 2024 NICE guidelines recommend surveillance every 2-3 years for Barrett's segments ≥3 cm, compared to every 3-5 years for segments <3 cm 3. This reflects the recognition that 3 cm represents a clinically meaningful threshold where cancer risk becomes substantial enough to warrant more intensive monitoring.
Important Nuances:
Risk modifiers beyond length should influence your surveillance interval within the 2-3 year range 1, 3:
- Male sex: 2-fold increased risk
- Smoking: 1.5-fold increased risk
- Advancing age: Incrementally increased risk
- Family history of esophageal cancer: Higher risk
For a 3 cm segment specifically, you're at the threshold where the segment is considered "long" by most definitions. A patient with a 3 cm segment who is male, older, and smokes should receive surveillance at the shorter end of the interval (every 2 years), while a younger female non-smoker might reasonably extend to 3 years.
Absolute Risk Perspective
While 0.3% annual risk sounds low, over a 10-year surveillance period, approximately 97% of patients with non-dysplastic Barrett's remain cancer-free 4. However, this also means that roughly 3% will develop HGD or cancer over that decade—a non-trivial proportion that justifies surveillance.
Common Pitfall to Avoid:
Do not dismiss surveillance in a 3 cm segment simply because the absolute annual risk is "only" 0.3%. The cumulative risk over years is meaningful, and importantly, all incident cancers detected during surveillance in these cohorts were early-stage and curable 5. This is the entire rationale for surveillance—catching cancer at a treatable stage.
Quality of the Index Endoscopy Matters
The 2025 AGA guideline emphasizes that 17% of Barrett's cancers are "post-endoscopy" cancers (missed at prior endoscopy) 1. For a 3 cm segment, ensure:
- High-quality examination with adequate biopsy sampling
- Consider repeat endoscopy within the first year if the index exam was suboptimal
- Use of Seattle protocol biopsies (4-quadrant biopsies every 2 cm)
The risk estimate of 0.3% per year assumes high-quality surveillance; poor-quality endoscopy increases the risk of interval cancers.